Compare

Lifevantage Corp vs Maravai Lifesciences Holdings, Inc. vs Cryoport, Inc. vs Rhythm Pharmaceuticals, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Lifevantage Corp LFVN	Maravai Lifesciences Holdings, Inc. MRVI	Cryoport, Inc. CYRX	Rhythm Pharmaceuticals, Inc. RYTM
Year ended	2026-06-30	2025-12-31	2025-12-31	2025-12-31
Revenue	$182.59M	$185.74M	$176.18M	$189.76M
Revenue growth (YoY)	-20.1%	-28.3%	+12.4%	+45.8%
Gross margin	77.6%	18.3%	47.1%	89.7% (computed)
Operating margin	3.3%	-115.9%	-20.9%	-101.2%
Net margin	2.8%	-70.4%	44.4%	-103.6%
Net income	$5.07M	-$130.77M	$78.30M	-$196.54M
EPS (Diluted)	$0.40	-$0.90	$1.40	-$3.11
Operating cash flow	$10.24M	-$57.57M	-$8.58M	-$115.67M
Free cash flow	$6.67M	-$70.72M	-$25.02M	-$116.63M
Cash & equivalents	n/a	$216.89M	$250.49M	$54.30M
Total assets	$62.11M	$770.58M	$764.99M	$480.20M
Total liabilities	$28.52M	$397.87M	$262.35M	$210.17M
Shareholders' equity	$33.59M	$212.38M	$502.64M	$139.07M
Return on year-end equity	15.1%	-61.6%	15.6%	-141.3%
Shares outstanding	12.52M	n/a	49.85M	67.21M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Lifevantage Corp	Maravai Lifesciences Holdings, Inc.	Cryoport, Inc.	Rhythm Pharmaceuticals, Inc.
Latest	$182.59M Ended 2026-06-30	$185.74M Ended 2025-12-31	$176.18M Ended 2025-12-31	$189.76M Ended 2025-12-31
1 year earlier	$228.53M Ended 2025-06-30	$259.19M Ended 2024-12-31	$156.77M Ended 2024-12-31	$130.13M Ended 2024-12-31
2 years earlier	$200.16M Ended 2024-06-30	$288.94M Ended 2023-12-31	$168.66M Ended 2023-12-31	$77.43M Ended 2023-12-31
3 years earlier	$213.40M Ended 2023-06-30	$883.00M Ended 2022-12-31	$237.28M Ended 2022-12-31	$23.64M Ended 2022-12-31
4 years earlier	$206.36M Ended 2022-06-30	$799.24M Ended 2021-12-31	$222.61M Ended 2021-12-31	$3.15M Ended 2021-12-31